CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| MDA2016-07-02 | CP-CTNet_CLO-MD Anderson | A Randomized, Double-blind, Placebo-controlled Study of 4-hydroxytamoxifen Topical Gel in Women with Mammographically Dense Breast | Cancer Prevention and Control CIRB | Available to Open |
| MDA2017-09-03 | CP-CTNet_CLO-MD Anderson | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers scheduled for Risk-reducing Salpingooophorectomy | Cancer Prevention and Control CIRB | Completed |
| MDA21-06-01 | CP-CTNet_CLO-MD Anderson | A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome | Cancer Prevention and Control CIRB | Available to Open |
| MDA2014-04-01 | CP-CTNet_CLO-MD Anderson | Alternative Dosing of Exemestane in Postmenopausal Women with Stage 0-II ER-Positive Breast Cancer: a Randomized Presurgical Trial | Cancer Prevention and Control CIRB | Completed |
| MDA2014-04-02 | CP-CTNet_CLO-MD Anderson | VADIS Trial: Phase II trial of Nelipepimut-S Peptide Vaccine in Women with DCIS of the Breast | Cancer Prevention and Control CIRB | Completed |
| MDA2013-02-02 | CP-CTNet_CLO-MD Anderson | Effect of Aspirin on Biomarkers of Barrett’s Esophagus After Successful Eradication of Barrett’s Esophagus with Radiofrequency Ablation | Cancer Prevention and Control CIRB | Completed |
| MDA2016-08-02 | CP-CTNet_CLO-MD Anderson | A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer | Cancer Prevention and Control CIRB | Completed |
| MAY2016-07-01F | CP-CTNet_CLO-Mayo Clinic | Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01 Weekly Erlotinib for Familial Adenomatous Polyposis | Cancer Prevention and Control CIRB | Completed |
| MAY2016-07-01 | CP-CTNet_CLO-Mayo Clinic | Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated with Familial Adenomatous Polyposis | Cancer Prevention and Control CIRB | Completed |
| MAY2015-05-01 | CP-CTNet_CLO-Mayo Clinic | Randomized, double-blind, placebo-controlled trial of Meriva® (curcuminoids) as a candidate chemoprevention agent for gastric carcinogenesis | Cancer Prevention and Control CIRB | Available to Open |